Atossa Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Listing Requirements
Portfolio Pulse from Benzinga Newsdesk
Atossa Therapeutics, Inc. (NASDAQ:ATOS) has regained compliance with the Nasdaq minimum closing bid price requirement for continued listing on The Nasdaq Capital Market. The company was previously not in compliance due to its common stock failing to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The company has made significant progress with its (Z)-endoxifen development program and has over $100 million cash with no debt.
July 13, 2023 | 8:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Atossa Therapeutics has regained compliance with Nasdaq's minimum bid price requirement, which could positively impact investor confidence. The company's strong financial position, with over $100 million in cash and no debt, also bodes well for its future prospects.
Regaining compliance with Nasdaq's minimum bid price requirement removes the risk of delisting, which can be a major concern for investors. This, combined with the company's strong financial position, could lead to increased investor confidence and a potential increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100